Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus THEOCLEAR L A 260.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus THEOCLEAR L A 260.
ASBRON vs THEOCLEAR L.A.-260
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing cAMP levels, and antagonizing adenosine receptors.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
Theophylline (THEOCLEAR L.A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/mL.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Category C
Category C
Bronchodilator
Bronchodilator